There was a 95.1% median reduction in HAE attacks compared with placebo over 16 weeks in the Phase 3 study for C1-esterase inhibitor SC (human) based on the recommended dose of 60 IU, with 40% attack free during this time [16]. Here, C1S is linked to hereditary angioedema.